Use of central institutional review boards for multicenter clinical trials in the United States: A review of the literature

The Society for Clinical Trials: May 10, 2013

Background To improve the efficiency of conducting multicenter clinical trials, the Food and Drug Administration, the Office of Human Research Protections, and the Department of Health and Human Services have expressed support for using a centralized institutional review board (IRB) process. However, research institutions differ in their willingness to defer to central IRBs. Read more